ActiveMax® Human CD19 μBeads, premium grade (for cells, Super stable)

ユーザーレビュー
製品番号/仕様
価格
数量
MBS-C035-2.5mg
$586.00
MBS-C035-10mg (2.5mg X 4)
$1440.00
ETA of in-stock products:2 business days
総アイテム数 製品金額$ 0

製品詳細

  • Product
    Size
    Amount
    ActiveMax® Human CD19 μBeads, premium grade (for cells, Super stable)
    2.5 mg
    2.5 × 10⁷ beads
    ActiveMax® Human CD19 μBeads, premium grade (for cells, Super stable)
    10 mg (2.5 mg × 4)
    1.0 × 10⁸ beads
  • Product Show

    CD19 PRODUCT SHOW

    This product can be directly isolated using conventional column-free magnetic stand (eg. Cat. MB-01/ MB-02/ MB-03/ MB-04). Please note that due to its micron-scale size, it is not compatible with commercially available column-based (M/D/L) magnetic separation systems.

  • Features

    1. Sterility
    2. Endotoxin content ≤0.002 EU/μg
    3. Mycoplasma
    4. Batch-to-batch consistency
  • Product Description

    ActiveMax® Human CD19 μBeads, premium grade (for cells) are uniform, superparamagnetic beads of 5.5 µm in diameter immobilized with Human CD19 protein expressed from human 293 cells (HEK293) and contains AA Pro 20 - Pro 278 (Accession # P15391-1).
    ActiveMax® Human CD19 μBeads, premium grade (for cells) are produced under sterile manufacturing conditions (ISO 5), and no animal- or human-derived components are used throughout the production process. It is produced under our rigorous quality control system that includes a comprehensive set of tests including sterility and endotoxin tests.
    Compared to MBS-C002, this product demonstrates superior stability and a longer shelf life, ensuring consistent and reliable performance over extended periods.

  • Application

    ActiveMax® Human CD19 μBeads, premium grade (for cells) are designed to stimulate in vitro CD19-specific CAR-T cells or UCAR-T cells, similar to the tumor cell lines that express human CD19 antigen. It can be used as follows:
    Evaluating the characteristics of CAR-T cells or UCAR-T cells.
    In vitro expansion of CD19-specific CAR-T cells or UCAR-T cells.
    In vitro enrichment of CD19-specific CAR-T cells or UCAR-T cells.

  • Reconstitution

    See Certificate of Analysis (CoA) for detailed instruction.

  • Storage

    This product is stable in storage under the following conditions: -20˚C for 12 months in lyophilized state. -70°C for 12 months under sterile conditions after reconstitution. 2-8°C for 2 week under sterile conditions after reconstitution.

    Please protect from light and avoid repeated freeze-thaw cycles. Immediate use after reconstitution is highly recommended.

  • Sterility

    Negative

  • Endotoxin

    Less than 2 EU per mg by the LAL method / rFC method.

  • Mycoplasma

    Negative

  • Important Note

    This product is for research use only and not intended for therapeutic or in vivo diagnostic use.

  • Formulation

    Lyophilized in PBS with 0.1% rHSA, pH 7.4. Trehalose is added as protectant before lyophilization.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

お客様はこちらも閲覧

データ表示

  • FACS Data

     CD19 FACS

    Assay of human CD19 protein on the μBeads surface by Flow cytomtry. The human CD19 conjugated on the μBeads (Cat. No. MBS-C035) surface were fluorescently stained using PE labeled anti-human CD19 antibody and analyzed by flow cytometry (QC tested).

    Protocol
  • Application Data

     CD19 APPLICATION DATA

    ActiveMax® Human CD19 μBeads, premium grade (for cells, Super stable) (Cat. No. MBS-C035) can activate CD19-specific CAR-T cells by detecting the secretion of IFN- γ in vitro (Routinely tested).

  •  CD19 APPLICATION DATA

    Enrichment of Anti-CD19+ CAR-T Cells Using ActiveMax® Human CD19 μBeads, Premium Grade (for cells, Super stable).
    For 2.5 × 10⁶ Anti-CD19 CAR-T cells with initial positivity rates of 59.05% (donor 1)and 31.18% (donor 2), respectively, significant enrichment was achieved using ActiveMax® Human CD19 μBeads, Premium Grade (for cells, Super stable) (Cat. No. MBS-C035) at Beads : cells ratios of 0.2:1, 1:1, and 5:1. At a Beads : cells ratio of 5:1, the enrichment efficiency reached 87% for the donor 1 and 95% for the donor 2.
    Beads enrichment efficiency=1-(untouched cells * ratio of CD19 CAR-T )/(Initial cells * ratio of CD19 CAR-T) * 100%.

ユーザーレビュー
コメントを投稿

最新の進展

 
医薬品開発の進捗
  • 英語名:

    B-lymphocyte antigen CD19

  • カテゴリ:

  • 市販の医薬品数:

    14 詳細

  • 治験医薬品数:

    435 詳細

  • 最新の開発ステージ:

    Approved

お問い合わせ
医薬品候補ライセンス
他の関連情報
  • 製品情報
  • 製品詳細
  • お客様はこちらも閲覧
  • データ表示
  • ユーザーレビュー
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8